Hypera S.A. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
July 28, 2022 at 07:33 pm EDT
Share
Hypera S.A. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net income was BRL 455.78 million compared to BRL 470.76 million a year ago. Basic earnings per share from continuing operations was BRL 0.72 compared to BRL 0.76 a year ago. Basic earnings per share was BRL 0.72324 compared to BRL 0.74514 a year ago. Diluted earnings per share was BRL 0.71238 compared to BRL 0.73618 a year ago.
For the six months, net income was BRL 803.45 million compared to BRL 776.11 million a year ago. Basic earnings per share from continuing operations was BRL 1.27 compared to BRL 1.25 a year ago. Basic earnings per share was BRL 1.27288 compared to BRL 1.22788 a year ago. Diluted earnings per share was BRL 1.2593 compared to BRL 1.21348 a year ago.
Hypera (formerly Hypermarcas) is the Brazilian leader in the manufacture and marketing of pharmaceutical products. The products are sold primarily under the Addera D3, Adocyl, AdultMax, Alivium, Apracur, Atroveran, Benegrip, Bigfral, Biotonico Fontoura, Coristina, Cremer, Doril, Engov, Epocler, Lisador and Neo Quimica. The activity is organized around 3 families of products :
- OTC medicines;
- prescription medicines;
- branded generic medicines.
HYPERA S.A. 
